Late-onset Pompe disease (LOPD) in Belgium: clinical characteristics and outcome measures.

BACKGROUND: Late-onset Pompe disease (LOPD) is a rare, hereditary, progressive disorder that is usually characterized by limb-girdle muscle weakness and/or respiratory insufficiency. LOPD is caused by mutations in the acid alpha-glucosidase (GAA) gene and treated with enzyme replacement therapy (ERT). METHODS: We studied the clinical, brain imaging, and genetic features of the Belgian cohort of late-onset Pompe disease patients (N = 52), and explored the sensitivity of different outcome measures, during a longitudinal period of 7 years (2010-2017), including the activity limitations ActivLim s... Mehr ...

Verfasser: Vanherpe, Pieternel
Fieuws, Steffen
D'Hondt, Ann
Bleyenheuft, Corinne
Demaerel, Philippe
De Bleecker, J
Van den Bergh, Peter
Baets, Jonathan
Remiche, Gauthier
Verhoeven, Kristof
Delstanche, Stéphanie
Toussaint, Michel
Buyse, Bertien
Van Damme, Philip
Depuydt, Christophe E
Claeys, Kristl G
Dokumenttyp: Artikel
Erscheinungsdatum: 2020
Verlag/Hrsg.: BioMed Central
Schlagwörter: Belgium / Delayed Diagnosis / Enzyme Replacement Therapy / Glycogen Storage Disease Type II / Humans / Middle Aged / Outcome Assessment / Health Care / alpha-Glucosidases / 6MWD / ActivLim / Belgian cohort / GSD2 / Glycogen storage disease type 2 / Respiratory
Sprache: Englisch
Permalink: https://search.fid-benelux.de/Record/base-26915488
Datenquelle: BASE; Originalkatalog
Powered By: BASE
Link(s) : http://hdl.handle.net/2078.1/253644